An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety and Sustained Efficacy of Denosumab (AMG162) in the Treatment of Postmenopausal Osteoporosis

Trial Profile

An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety and Sustained Efficacy of Denosumab (AMG162) in the Treatment of Postmenopausal Osteoporosis

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Denosumab (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Adverse reactions
  • Acronyms FREEDOM extension
  • Sponsors Amgen
  • Most Recent Events

    • 04 Apr 2017 Combined results of FREEDOM and FREEDOM- extension study (n=794) presented at The 99th Annual Meeting of the Endocrine Society
    • 04 Apr 2017 Results of incidences of vertebral fracture after discontinuation of denosumab treatment in patients from FREEDOM trial and its extension study (n=470) presented at The 99th Annual Meeting of the Endocrine Society
    • 17 Apr 2016 Results of FREEDOM and FREEDOM extension studies presented at the 2016 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top